PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes

British Journal of Pharmacology

Volumn 171, Issue 19, 2014, Pages 4504-4519

  Chien, Peter Tzu Yu ^a,b   Hsieh, Hsi Lung ^c   Chi, Pei Ling ^b   Yang, Chuen Mao ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CELECOXIB; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; HELENALIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; PROTEIN C JUN; PROTEIN P42; PROTEINASE ACTIVATED RECEPTOR 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; TANSHINONE IIA; THROMBIN; TRANSCRIPTION FACTOR AP 1; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PTGER2 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; XANTHONE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; GENETIC TRANSFECTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENETICS; METABOLISM;

CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; NF-KAPPA B; RECEPTOR, PAR-1; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RNA, MESSENGER; THROMBIN; TRANSCRIPTION FACTOR AP-1; XANTHONES;

EID: 84927592793     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12794     Document Type: Article

References (63)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Ariens RA, (2013). Fibrin(ogen) and thrombotic disease. J Thromb Haemost 11 (Suppl. 1): 294-305.
4. Barnes JA, Singh S, Gomes AV, (2004). Protease activated receptors in cardiovascular function and disease. Mol Cell Biochem 263: 227-239.
5. Chang KT, Taylor GP, Meschino WS, Kantor PF, Cutz E, (2010). Mitogenic cardiomyopathy: a lethal neonatal familial dilated cardiomyopathy characterized by myocyte hyperplasia and proliferation. Hum Pathol 41: 1002-1008.
6. Coughlin SR, (1999). How the protease thrombin talks to cells. Proc Natl Acad Sci U S A 96: 11023-11027.
7. Coughlin SR, (2000). Thrombin signalling and protease-activated receptors. Nature 407: 258-264.
8. Duvivier J, Wolf D, Heusghem C, (1975). Enzymatic properties of prostaglandin synthetase from bovine seminal vesicles. Biochimie 57: 521-528.
9. Glembotski CC, Irons CE, Krown KA, Murray SF, Sprenkle AB, Sei CA, (1993). Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem 268: 20646-20652.
10. 2 promotes hepatocellular carcinoma cell proliferation through EP2 prostanoid receptor]. Nan Fang Yi Ke Da Xue Xue Bao 31: 1564-1567.
11. Harding P, Murray DB, (2011). The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure. Life Sci 89: 671-676.
12. Heineke J, Molkentin JD, (2006). Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600.
13. Herbert JM, Dupuy E, Laplace MC, Zini JM, Bar Shavit R, Tobelem G, (1994). Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J 303: 227-231.
14. Hinrichsen R, Haunso S, Busk PK, (2007). Different regulation of p27 and Akt during cardiomyocyte proliferation and hypertrophy. Growth Factors 25: 132-140.
15. 2 production in rat vascular smooth muscle cells. Biochim Biophys Acta 1783: 1563-1575.
16. 2 promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol Med 6: 496-503.
17. Isenovic ER, Soskic S, Trpkovic A, Dobutovic B, Popovic M, Gluvic Z, et al. (2010). Insulin, thrombine, ERK1/2 kinase and vascular smooth muscle cells proliferation. Curr Pharm Des 16: 3895-3902.
18. Ito K, Date T, Ikegami M, Hongo K, Fujisaki M, Katoh D, et al. (2013). An immunohistochemical analysis of tissue thrombin expression in the human atria. PLoS ONE 8: e65817.
19. Jaffre F, Friedman AE, Hu Z, Mackman N, Blaxall BC, (2012). beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation 125: 2993-3003.
20. 2-induced proliferation of human umbilical cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression. J Cell Physiol 227: 3756-3767.
21. Jug B, Vene N, Salobir BG, Sebestjen M, Sabovic M, Keber I, (2009). Procoagulant state in heart failure with preserved left ventricular ejection fraction. Int Heart J 50: 591-600.
22. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL, (2007). Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46: 108-125.
23. Kardami E, Banerji S, Doble BW, Dang X, Fandrich RR, Jin Y, et al. (2003). PKC-dependent phosphorylation may regulate the ability of connexin43 to inhibit DNA synthesis. Cell Commun Adhes 10: 293-297.
24. Kawamura N, Kubota T, Kawano S, Monden Y, Feldman AM, Tsutsui H, et al. (2005). Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res 66: 520-529.
25. 2 formation in human lung epithelial cells. J Pharmacol Exp Ther 315: 576-589.
26. Kotlyar E, Vita JA, Winter MR, Awtry EH, Siwik DA, Keaney JF Jr, et al. (2006). The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail 12: 122-127.
27. Kreda SM, Seminario-Vidal L, van Heusden CA, O'Neal W, Jones L, Boucher RC, et al. (2010). Receptor-promoted exocytosis of airway epithelial mucin granules containing a spectrum of adenine nucleotides. J Physiol 588: 2255-2267.
28. Kunisch E, Jansen A, Kojima F, Loffler I, Kapoor M, Kawai S, et al. (2009). Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-alpha on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol 183: 1328-1336.
29. 2/cyclin D1-dependent VSMCs proliferation via STAT3 activation: role of PKCs-dependent NADPH oxidase/ROS generation. Biochem Pharmacol 85: 954-964.
30. Li W, Olshansky B, (2011). Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev 16: 137-145.
31. 2 mediates proliferation and chloride secretion in ADPKD cystic renal epithelia. Am J Physiol Renal Physiol 303: F1425-F1434.
32. 2 release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. J Cell Biochem 108: 1143-1152.
33. Lu SY, Sontag DP, Detillieux KA, Cattini PA, (2008). FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. Am J Physiol Cell Physiol 294: C1242-C1249.
34. Moshal KS, Tyagi N, Henderson B, Ovechkin AV, Tyagi SC, (2005a). Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol 288: H2770-H2777.
35. Moshal KS, Tyagi N, Moss V, Henderson B, Steed M, Ovechkin A, et al. (2005b). Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med 9: 704-713.
36. Nadal-Ginard B, Kajstura J, Leri A, Anversa P, (2003). Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 92: 139-150.
37. Norman DA, Yacoub MH, Barton PJ, (1998). Nuclear factor NF-kappa B in myocardium: developmental expression of subunits and activation by interleukin-1 beta in cardiac myocytes in vitro. Cardiovasc Res 39: 434-441.
38. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, et al. (2007). Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 116: 2298-2306.
39. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Research 42 (Database Issue): D1098-1106.
40. Ravingerova T, Barancik M, Strniskova M, (2003). Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247: 127-138.
41. Ritter O, Neyses L, (2003). The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med 9: 313-321.
42. Rolin S, Hanson J, Vastersaegher C, Cherdon C, Pratico D, Masereel B, et al. (2007). BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents. Prostaglandins Other Lipid Mediat 84: 14-23.
43. Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, et al. (2000). Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res 86: 1054-1061.
44. Sabri A, Short J, Guo J, Steinberg SF, (2002). Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res 91: 532-539.
45. Sabri A, Alcott SG, Elouardighi H, Pak E, Derian C, Andrade-Gordon P, et al. (2003). Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem 278: 23944-23954.
46. Saito T, Giaid A, (1999). Cyclooxygenase-2 and nuclear factor-kappaB in myocardium of end stage human heart failure. Congest Heart Fail 5: 222-227.
47. Sawada T, Minamino T, Fu HY, Asai M, Okuda K, Isomura T, et al. (2010). X-box binding protein 1 regulates brain natriuretic peptide through a novel AP1/CRE-like element in cardiomyocytes. J Mol Cell Cardiol 48: 1280-1289.
48. 2 formation caused by proteinase-activated receptor-1 activation in rat gastric mucosal epithelial cells. Biochem Pharmacol 73: 103-114.
49. 2 release in rat gastric epithelial RGM1 cells. J Cell Biochem 112: 909-915.
50. 2+-dependent signaling pathways. J Biol Chem 284: 20638-20648.
51. Shah R, (2009). Protease-activated receptors in cardiovascular health and diseases. Am Heart J 157: 253-262.
52. Smith WL, DeWitt DL, Garavito RM, (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182.
53. Soh UJ, Dores MR, Chen B, Trejo J, (2010). Signal transduction by protease-activated receptors. Br J Pharmacol 160: 191-203.
54. Streicher JM, Wang Y, (2008). The role of COX-2 in heart pathology. Cardiovasc Hematol Agents Med Chem 6: 69-79.
55. Streicher JM, Kamei K, Ishikawa TO, Herschman H, Wang Y, (2010). Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. J Mol Cell Cardiol 49: 88-94.
56. Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. (2006). Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem 281: 11792-11804.
57. Tu VC, Bahl JJ, Chen QM, (2003). Distinct roles of p42/p44(ERK) and p38 MAPK in oxidant-induced AP-1 activation and cardiomyocyte hypertrophy. Cardiovasc Toxicol 3: 119-133.
58. Vouret-Craviari V, Van Obberghen-Schilling E, Rasmussen UB, Pavirani A, Lecocq JP, Pouyssegur J, (1992). Synthetic alpha-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. Mol Biol Cell 3: 95-102.
59. Wang H, Wen S, Bunnett NW, Leduc R, Hollenberg MD, MacNaughton WK, (2008). Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. J Biol Chem 283: 809-815.
60. Wang Y, (2007). Mitogen-activated protein kinases in heart development and diseases. Circulation 116: 1413-1423.
61. 2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109: 2462-2468.
62. Yang CM, Lee IT, Lin CC, Wang CH, Cherng WJ, Hsiao LD, (2013). c-Src-dependent MAPKs/AP-1 activation is involved in TNF-alpha-induced matrix metalloproteinase-9 expression in rat heart-derived H9c2 cells. Biochem Pharmacol 85: 1115-1123.
63. 2 promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 113: 104-114.